


**Product Name** : Fenebrutinib  
**Cat. No.** : PC-45739  
**CAS No.** : 1434048-34-6  
**Molecular Formula** : C<sub>37</sub>H<sub>44</sub>N<sub>8</sub>O<sub>4</sub>  
**Molecular Weight** : 664.7964  
**Target** : BTK  
**Solubility** : DMSO: ≥ 23 mg/mL



### Biological Activity

Fenebrutinib (RG7845, GDC-0853) is an orally bioavailable, selective, non-covalent and reversible **BTK** inhibitor with IC<sub>50</sub> of 2-9 nM.

Fenebrutinib (RG7845, GDC-0853) has demonstrated efficacy in pre-clinical autoimmune disease models and is being developed for the treatment of rheumatoid arthritis and lupus, with future development for other autoimmune indications.

### References

Erickson RI, et al. *J Pharmacol Exp Ther*. 2017 Jan;360(1):226-238.

Katsumoto, T. 2016 ACR/ARHP Annual Meeting (2016).

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com